Open the drawer. Most founders at your level have one: the supplements, the stack assembled from a podcast and a clever friend and a clinic in California, the compounds with the interesting names, possibly the peptides, the things taken because someone credible said they sharpen focus or speed recovery or buy years. You reached for these first. Nearly everyone does. And the reason you reached for them first is very close to the reason they mostly haven't done much.
The performance field is built to sell the top of the pyramid. The base (sleep, glucose stability, the state of the autonomic system) is unglamorous, unbranded, and impossible to package as a breakthrough. The accelerants are everything the base is not: novel, acute, demonstrable. You take the thing, you feel the thing; there is a product, a purchase, and a story to tell at dinner. Nobody has ever built a business selling you a regular bedtime. So the market tilts structurally toward the compound and away from the condition it acts on, and over the years it has quietly trained you to approach your own physiology from the wrong end, reaching for the intervention that might add a few percent while the foundation it depends on sits broken underneath it.
The thing the field has no incentive to tell you is that an accelerant on a broken base is not a smaller version of the accelerant on a sound one. It is a different transaction, usually a worse one, and it fails in three distinct ways. You have probably paid for all three.
The first failure is inertness. A great many accelerants act on a substrate the foundation is supposed to supply. A compound that supports recovery does nothing measurable in a system that isn't sleeping long enough to recover, because recovery is the raw material it works on, and you haven't made any. You are supplementing a process that isn't running. The money is spent, the capsule is taken, nothing happens, and the conclusion you reasonably draw is that the compound was overhyped, when the actual problem was that it arrived with nothing to work on.
The second failure is worse than inertness. Push an accelerant into a system with no capacity to absorb the push and you don't get performance; you get damage. Sport learned this decades ago and built the entire logic of training around it. No competent coach hands a novice the advanced programme, not because the novice hasn't earned it, but because the advanced stimulus acts on adaptations the novice doesn't yet have. Load intensity onto an unbuilt base and the tissue that should adapt tears instead. The sequence is not a hierarchy of reward. It is dictated by what the body can currently metabolise, and the body is unsentimental about it.
The third failure is the most expensive, because it feels like success. An accelerant deployed on a broken foundation can mask the break. You have already met the clearest case in this series: the stimulant that carries you through the day on four hours' sleep does not restore the capacity the sleep would have built. It borrows more against an already overdrawn account and hides the balance. You feel handled. You are not handled; you are further behind, with the warning light taped over. This is the real cost of starting at the wrong end. The whole argument of this series is that the founder's instrument must be able to report on its own state, and an accelerant that makes a degraded system feel fine is corrupting exactly that signal. It doesn't just fail to fix the foundation. It removes the pressure to.
None of this is an argument against accelerants. They are real, several are genuinely useful, and on a sound base some of them do precisely what they claim. It is an argument about order, and about the fact that the order is not a matter of taste. This is not delayed gratification, not self-denial, not earning the interesting stuff by suffering the boring stuff first. It is mechanism. The accelerant is an investment that only pays out on a functioning system. Deployed onto a broken one, it is wasted at best and actively harmful at worst. Sequence is not the polite version of the plan. Sequence is whether the plan can work at all.
Which is why the honest version of this sometimes disappoints in the first conversation. The founder who arrives wanting the peptide protocol and the exotic stack, and is told that the first job is the sleep and the glucose and the unglamorous base, hears a downgrade. It is the opposite. It is the only order in which the exotic stack was ever going to earn its price.
You didn't need the accelerants sooner. You needed the foundation they were quietly waiting on.